Salvatore Novello

Differential role of C-terminal truncations on alpha-synuclein pathology and Lewy body formation

Nuclear ASC speck formation in microglia is associated with inflammasome priming and is exacerbated in LRRK2-G2019S Parkinson’s disease

Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice

Mitochondrial P2X7 Receptor Localization Modulates Energy Metabolism Enhancing Physical Performance

In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity

Early Dysfunction of Substantia Nigra Dopamine Neurons in the ParkinQ311X Mouse

Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates

Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease

Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity

Pharmacological Antagonism of Kainate Receptor Rescues Dysfunction and Loss of Dopamine Neurons in a Mouse Model of Human Parkin-induced Toxicity

The P2X7 receptor localizes to the mitochondria, modulates mitochondrial energy metabolism and enhances physical performance

Autophagy and LRRK2 in the Aging Brain

Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in non-human primates

G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice

Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia

Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease

NOP Receptor Ligands and Parkinson’s Disease

Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice

Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia

Anti‐Parkinsonian and anti‐dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists